Litcius/Paper detail

Copper chelating cyclic peptidomimetic inhibits Aβ fibrillogenesis

Sujan Kalita, Sourav Kalita, Altaf Hussain Kawa, Sukesh Shill, Anjali Gupta, Sachin Kumar, Bhubaneswar Mandal

2022RSC Medicinal Chemistry18 citationsDOIOpen Access PDF

Abstract

, thereby exhibiting profound selectivity, probed using UV-visible spectroscopy, thioflavin T (ThT) fluorescence assay, tyrosine (TYR10) fluorescence assay, isothermal titration calorimetry (ITC) and transmission electron microscopy (TEM). The non-toxicity of the designed peptidomimetics and their ability to reduce aggregating Aβ-fragment induced cytotoxicity was confirmed by the MTT assay on the mouse neuronal cell line. Further, the molecular interaction between the peptidomimetics and the Aβ-fragment was confirmed by Förster resonance energy transfer (FRET) studies using fluorescently labeled analogs. Cytotoxicity and cell internalization were also confirmed. A preliminary mechanistic investigation indicates that the peptidomimetic works by a synergistic effect of conformational restriction and metal sequestration. Such peptidomimetics can shed light on the mechanism of aggregation and a novel therapeutic approach.

Topics & Concepts

PeptidomimeticFibrillogenesisCopperChelationChemistryCombinatorial chemistryStereochemistryBiochemistryOrganic chemistryFibrilPeptideAlzheimer's disease research and treatmentsProtein Structure and DynamicsComputational Drug Discovery Methods